Global Microfluidic Immunoassay Market

Microfluidic Immunoassay Market Size, Share, Growth Analysis, By Technology(Cardiac Biomarker Detection, Inflammatory Biomarker Detection, Other Biomarkers and Emerging Biomarkers), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35H2075 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 36 | Figures: 74

Microfluidic Immunoassay Market News

  • In October 2022, The establishment of the Dissolution Centre of Excellence (CoE) in Craven Arms, United Kingdom, was announced by Agilent Technologies Inc. (UK). The core of Agilent's dissolution business, including research and development, quality, support, applications, marketing, and more, will be housed in the recently remodeled facilities.
  • In October 2022, GE Healthcare proudly introduced Omni Legendi, the first system on its all-new, all-digital PET/CT platform. 
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Microfluidic Immunoassay Market size was valued at USD 25597.94 million in 2019 and is poised to grow from USD 28718.33 million in 2023 to USD 71897.42 million by 2031, growing at a CAGR of 12.19% in the forecast period (2024-2031).

microfluidic immunoassay market is highly competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'Abbott Laboratories', 'Bio-Rad Laboratories', ' Becton, Dickinson and Company ', ' Cepheid Inc. ', ' Danaher Corporation ', ' Fluidigm Corporation ', ' GE Healthcare ', ' Illumina Inc. ', ' Luminex Corporation ', ' Merck Millipore ', ' NanoString Technologies Inc. ', ' PerkinElmer Inc. ', ' QIAGEN N.V. ', ' Randox Laboratories Ltd. ', ' Roche Diagnostics ', ' Siemens Healthineers AG ', ' Thermo Fisher Scientific Inc. ', ' Tosoh Corporation ', ' Wako Pure Chemical Industries, Ltd. ', ' Waters Corporation '

For the companies in the microfluidic immunoassay market, emerging economies and novel technologies like paper-based microfluidics are projected to present several prospects for expansion. High growth in emerging economies is attributed to a number of factors, including an ageing population, a sizable patient population suffering from infectious and non-communicable diseases, an increase in R&D funding, a rise in the demand for high-quality healthcare, rising disposable income, and improved healthcare infrastructure.

Recently, there has been a lot of interest in microfluidic technology. This is primarily because combining the entire laboratory technique onto a single chip has reduced the need for bulky tools. The development of LOC technology took over two decades, and materials were employed in the creation of the devices. For the production of microfluidics-based POC cartridges for developing nations, paper is getting a lot of interest. This is due to a number of benefits of paper material, including the fact that it is an incredibly affordable substrate material, is suitable for many medical applications, and transfers fluid by capillary forces without the need for external forces. There is currently a lot of commercial and academic research being done in the area of paper-based microfluidics.

The market for microfluidic immunoassays was dominated by North America, which was followed by Europe, Asia-Pacific, Latin America, the Middle East, and Africa. However, the Asia Pacific region is anticipated to grow at the fastest CAGR during the forecast period. This is largely because of the region's economies' accelerated growth, improved healthcare infrastructure, increased accessibility to healthcare services, and innovative products. It is also because of the aging population's increased risk of infectious and noncommunicable diseases, rising disposable income, and ongoing investment and focus by major players in emerging Asian markets.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Microfluidic Immunoassay Market

Report ID: SQMIG35H2075

$5,300
BUY NOW GET FREE SAMPLE